ArticleJapanese journal of ophthalmology2025
Evaluating efficacy of 0.125% atropine using a myopia progression machine learning model.
Article in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Performance and Implementation of AI-Enabled Paediatric Ophthalmic Screening, Triage, Diagnosis, and Surveillance in Primary, Community, and Referral-Linked Pathways: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Machine learning identifies pupil size and corneal thickness as key predictors of axial elongation rate.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the usefulness of a machine learning (ML) model that can predict the natural course of childhood myopia in evaluation of the inhibitory effects of 0.125% atropine on the progression of childhood myopia. STUDY
designRetrospective, cohort study.
methodsA retrospective analysis was conducted on children treated daily with 0.125% atropine eye drops. The children were classified into 6-, 12-, 18-, 24-, and 30-month group based on the treatment duration. Spherical equivalents (SE) at the last treatment time point were compared with the pretreatment and ML-predicted SE. The myopia suppression rate due to treatment was calculated based on the first- and ML-predicted SE.
resultsA total of 771 eyes (402 boys and 369 girls) from 397 children were included. The participants' mean age was 8.0 ± 1.5 years. The first SE of -2.87 ± 1.67 diopters (D), treatment led to a mean SE of -3.44 ± 1.90 D, showing a significant reduction in myopia progression compared to the ML model's prediction of -4.12 ± 1.75 D. Except for the 6-month group, the last SE was statistically significantly less myopic than the predicted SE, indicating that treatment suppressed progression compared to the natural course. The mean myopia suppression rate was 53.5%, with definite differences between the groups.
conclusionTreatment with 0.125% atropine may suppress myopia progression in children compared with the ML child myopia prediction model. The application of a machine learning model to predict myopia progression may assist in evaluating the efficacy of 0.125% atropine treatment.
Indexed as
Identifiers
40372543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.